SCHEMBL1876992

SCHEMBL1876992

COc1cccc(-c2noc(N)c2-c2ccncn2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK11 Q15759 2/20 0.57
MAPK14 Q16539 2/20 0.57
MAPK9 P45984 1/20 0.57
MAPK10 P53779 1/20 0.57
TP53 P04637 3/20 0.55
HPGD P15428 2/20 0.55
HTT P42858 1/20 0.55
NPC1 O15118 4/20 0.45
RAB9A P51151 4/20 0.45
TDO2 P48775 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.43
PKM P14618 1/20 0.43
GRM5 P41594 1/20 0.43
CLK4 Q9HAZ1 2/20 0.43
DYRK1A Q13627 1/20 0.43
PIK3CD O00329 1/20 0.42
ABL1 P00519 1/20 0.42
EGFR P00533 1/20 0.42
HCK P08631 1/20 0.42
SRC P12931 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1882263 0.85 MAPK14 (0.70) MAPK11MAPK14MAPK9MAPK10NPC1
SCHEMBL27744977 0.85 TP53 (0.60) MAPK11MAPK14TP53HPGDHTT
SCHEMBL1874142 0.84 MAPK14 (0.61) MAPK11MAPK14MAPK9MAPK10NPC1
SCHEMBL1872450 0.83 EGFR (0.54) MAPK11MAPK14MAPK9MAPK10PIK3CD
SCHEMBL1874890 0.82 MAPK14 (0.62) MAPK11MAPK14MAPK9MAPK10HTT
SCHEMBL1878815 0.81 MAPK14 (0.72) MAPK11MAPK14MAPK9MAPK10TP53
SCHEMBL1879874 0.81 MAPK14 (0.61) MAPK11MAPK14MAPK9MAPK10HPGD
SCHEMBL1880334 0.81 MAPK14 (0.61) MAPK11MAPK14MAPK9MAPK10TP53
SCHEMBL1878049 0.81 MAPK14 (0.74) MAPK11MAPK14MAPK9MAPK10TDO2
SCHEMBL1878304 0.80 MAPK14 (0.59) MAPK11MAPK14MAPK9MAPK10ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1832584-B1 PYRIMIDINYLISOXAZOLE DERIVATIVE ASKA PHARM CO LTD (JP) 2011-12-21 EP disclosed
US-7939536-B2 5-[(2-chlorophenyl)acetylamino]-3-(4-fluorophenyl)-4-(4-pyrimidinyl)isoxazole; p 38MAP kinase inhibitor; tumor necrosis factor, interleukin, or cyclooxygenase-II related diseases; antiinflammatory, anticarcinogenic, antidiabetic agent ASKA PHARMACEUTICAL CO., LTD. (JP) 2011-05-10 US disclosed
US-20080114003-A1 Pyrimidinylisoxazole Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2008-05-15 US disclosed
EP-1832584-A1 PYRIMIDINYLISOXAZOL DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2007-09-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114003-A1 Pyrimidinylisoxazole Derivatives MAPK3, MAPK7, MAP3K7 MAPK11 42/4885MAPK14 29/4885MAPK9 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.